Combined therapy: what does acamprosate and naltrexone combination tell us?
Standard
Combined therapy: what does acamprosate and naltrexone combination tell us? / Kiefer, Falk; Wiedemann, Klaus.
in: ALCOHOL ALCOHOLISM, Jahrgang 39, Nr. 6, 6, 2004, S. 542-547.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Combined therapy: what does acamprosate and naltrexone combination tell us?
AU - Kiefer, Falk
AU - Wiedemann, Klaus
PY - 2004
Y1 - 2004
N2 - AIMS: Relapse prevention treatment with both acamprosate and naltrexone has been shown to be efficacious in the treatment of alcoholism. Whereas both compounds act pharmacologically differently, there is up to now only limited evidence as to whether combined treatment is efficacious and pharmacologically safe. It remains to be answered whether data justify the combination of both drugs in clinical practice. METHODS: Review of the three pre-clinical and four clinical studies that have been published to date on either combined tolerability or efficacy. RESULTS: Data available up to now show no occurrence of severe adverse events during combined treatment. Diarrhoea and nausea were shown to be the most significant side-effects. Whereas pre-clinical studies regarding efficacy of combined treatment are not yet conclusive, clinical data show the superiority of combined treatment compared with both placebo and acamprosate monotherapy. The synergistic effect of combined treatment remained after 12 weeks of drug-free follow-up. CONCLUSIONS: The combination of acamprosate with naltrexone in a clinical sample seems to be efficacious and safe. Numerous alcohol dependent patients could benefit, particularly those that responded insufficiently on monotherapeutic treatment with either acamprosate or naltrexone.
AB - AIMS: Relapse prevention treatment with both acamprosate and naltrexone has been shown to be efficacious in the treatment of alcoholism. Whereas both compounds act pharmacologically differently, there is up to now only limited evidence as to whether combined treatment is efficacious and pharmacologically safe. It remains to be answered whether data justify the combination of both drugs in clinical practice. METHODS: Review of the three pre-clinical and four clinical studies that have been published to date on either combined tolerability or efficacy. RESULTS: Data available up to now show no occurrence of severe adverse events during combined treatment. Diarrhoea and nausea were shown to be the most significant side-effects. Whereas pre-clinical studies regarding efficacy of combined treatment are not yet conclusive, clinical data show the superiority of combined treatment compared with both placebo and acamprosate monotherapy. The synergistic effect of combined treatment remained after 12 weeks of drug-free follow-up. CONCLUSIONS: The combination of acamprosate with naltrexone in a clinical sample seems to be efficacious and safe. Numerous alcohol dependent patients could benefit, particularly those that responded insufficiently on monotherapeutic treatment with either acamprosate or naltrexone.
M3 - SCORING: Zeitschriftenaufsatz
VL - 39
SP - 542
EP - 547
JO - ALCOHOL ALCOHOLISM
JF - ALCOHOL ALCOHOLISM
SN - 0735-0414
IS - 6
M1 - 6
ER -